Logo image of SNDX

SYNDAX PHARMACEUTICALS INC (SNDX) Stock Fundamental Analysis

NASDAQ:SNDX - Nasdaq - US87164F1057 - Common Stock - Currency: USD

10.35  +0.78 (+8.15%)

After market: 10.3301 -0.02 (-0.19%)

Fundamental Rating

2

Taking everything into account, SNDX scores 2 out of 10 in our fundamental rating. SNDX was compared to 553 industry peers in the Biotechnology industry. SNDX has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, SNDX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SNDX has reported negative net income.
SNDX had a negative operating cash flow in the past year.
SNDX had negative earnings in 4 of the past 5 years.
SNDX had negative operating cash flow in 4 of the past 5 years.
SNDX Yearly Net Income VS EBIT VS OCF VS FCFSNDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

With a Return On Assets value of -51.69%, SNDX perfoms like the industry average, outperforming 48.46% of the companies in the same industry.
SNDX's Return On Equity of -154.01% is on the low side compared to the rest of the industry. SNDX is outperformed by 62.39% of its industry peers.
Industry RankSector Rank
ROA -51.69%
ROE -154.01%
ROIC N/A
ROA(3y)-36.06%
ROA(5y)-25.66%
ROE(3y)-60.12%
ROE(5y)-40.97%
ROIC(3y)N/A
ROIC(5y)N/A
SNDX Yearly ROA, ROE, ROICSNDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

SNDX has a Gross Margin of 52.27%. This is in the better half of the industry: SNDX outperforms 77.22% of its industry peers.
SNDX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 52.27%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SNDX Yearly Profit, Operating, Gross MarginsSNDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

3

2. Health

2.1 Basic Checks

SNDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SNDX has more shares outstanding
The number of shares outstanding for SNDX has been increased compared to 5 years ago.
SNDX has a worse debt/assets ratio than last year.
SNDX Yearly Shares OutstandingSNDX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
SNDX Yearly Total Debt VS Total AssetsSNDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -2.54, we must say that SNDX is in the distress zone and has some risk of bankruptcy.
SNDX has a Altman-Z score (-2.54) which is comparable to the rest of the industry.
SNDX has a Debt/Equity ratio of 1.54. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of SNDX (1.54) is worse than 79.75% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.54
Debt/FCF N/A
Altman-Z -2.54
ROIC/WACCN/A
WACC9.58%
SNDX Yearly LT Debt VS Equity VS FCFSNDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

SNDX has a Current Ratio of 5.80. This indicates that SNDX is financially healthy and has no problem in meeting its short term obligations.
SNDX has a Current ratio of 5.80. This is comparable to the rest of the industry: SNDX outperforms 59.86% of its industry peers.
SNDX has a Quick Ratio of 5.75. This indicates that SNDX is financially healthy and has no problem in meeting its short term obligations.
SNDX has a better Quick ratio (5.75) than 60.58% of its industry peers.
Industry RankSector Rank
Current Ratio 5.8
Quick Ratio 5.75
SNDX Yearly Current Assets VS Current LiabilitesSNDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

SNDX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.88%.
The Revenue has been growing by 73.64% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-19.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-15.29%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-44.66%
Revenue growth 5Y73.64%
Sales Q2Q%N/A

3.2 Future

SNDX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.67% yearly.
Based on estimates for the next years, SNDX will show a very strong growth in Revenue. The Revenue will grow by 45.84% on average per year.
EPS Next Y-5.6%
EPS Next 2Y12.58%
EPS Next 3Y14.88%
EPS Next 5Y16.67%
Revenue Next Year27.71%
Revenue Next 2Y61.95%
Revenue Next 3Y54.37%
Revenue Next 5Y45.84%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
SNDX Yearly Revenue VS EstimatesSNDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
SNDX Yearly EPS VS EstimatesSNDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SNDX. In the last year negative earnings were reported.
Also next year SNDX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNDX Price Earnings VS Forward Price EarningsSNDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SNDX Per share dataSNDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

SNDX's earnings are expected to grow with 14.88% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.58%
EPS Next 3Y14.88%

More info and screens

0

5. Dividend

5.1 Amount

SNDX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SYNDAX PHARMACEUTICALS INC

NASDAQ:SNDX (7/29/2025, 5:35:53 PM)

After market: 10.3301 -0.02 (-0.19%)

10.35

+0.78 (+8.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-05 2025-05-05/amc
Earnings (Next)08-11 2025-08-11
Inst Owners120.64%
Inst Owner Change0.06%
Ins Owners1.21%
Ins Owner Change11.69%
Market Cap890.62M
Analysts85.26
Price Target34.34 (231.79%)
Short Float %27.9%
Short Ratio11.85
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-171.41%
Min EPS beat(2)-370.62%
Max EPS beat(2)27.8%
EPS beat(4)3
Avg EPS beat(4)-78.74%
Min EPS beat(4)-370.62%
Max EPS beat(4)27.8%
EPS beat(8)7
Avg EPS beat(8)-34.3%
EPS beat(12)11
Avg EPS beat(12)-20.85%
EPS beat(16)14
Avg EPS beat(16)16.28%
Revenue beat(2)1
Avg Revenue beat(2)-27.55%
Min Revenue beat(2)-91.24%
Max Revenue beat(2)36.14%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.55%
PT rev (3m)-3.05%
EPS NQ rev (1m)-0.58%
EPS NQ rev (3m)-1.52%
EPS NY rev (1m)-1.25%
EPS NY rev (3m)-0.03%
Revenue NQ rev (1m)1.58%
Revenue NQ rev (3m)37.14%
Revenue NY rev (1m)0.82%
Revenue NY rev (3m)46.13%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 20.37
P/FCF N/A
P/OCF N/A
P/B 4.14
P/tB 4.14
EV/EBITDA N/A
EPS(TTM)-3.86
EYN/A
EPS(NY)-2.73
Fwd EYN/A
FCF(TTM)-3.33
FCFYN/A
OCF(TTM)-3.33
OCFYN/A
SpS0.51
BVpS2.5
TBVpS2.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -51.69%
ROE -154.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 52.27%
FCFM N/A
ROA(3y)-36.06%
ROA(5y)-25.66%
ROE(3y)-60.12%
ROE(5y)-40.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 1.54
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.8
Quick Ratio 5.75
Altman-Z -2.54
F-Score3
WACC9.58%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-15.29%
EPS Next Y-5.6%
EPS Next 2Y12.58%
EPS Next 3Y14.88%
EPS Next 5Y16.67%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-44.66%
Revenue growth 5Y73.64%
Sales Q2Q%N/A
Revenue Next Year27.71%
Revenue Next 2Y61.95%
Revenue Next 3Y54.37%
Revenue Next 5Y45.84%
EBIT growth 1Y-30.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26.51%
EBIT Next 3Y25.41%
EBIT Next 5YN/A
FCF growth 1Y-118.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-118.75%
OCF growth 3YN/A
OCF growth 5YN/A